bluebird bio, Inc. - BLUE STOCK NEWS

bluebird bio (Nasdaq: BLUE) has announced an inducement grant of stock options to its new controller and vice president of accounting, Joe Ewer. The Compensation Committee approved options to purchase 38,200 shares of common stock, with a grant date of August 1, 2024. The options have an exercise price of $1.08 per share, equal to the fair market value on the grant date. These options vest over four years, with 25% vesting after one year and the remainder vesting monthly. The options have a 10-year term and were granted as an inducement for Mr. Ewer's employment, in accordance with NASDAQ Listing Rule 5635(c)(4).

Bluebird bio (Nasdaq: BLUE) announced the approval of an inducement grant of 300,000 stock options to its new CFO, James Sterling. This grant, approved by the Compensation Committee, is in line with Nasdaq Listing Rule 5635(c)(4) and has a grant date of July 1, 2024. The options are priced at $0.98 per share, reflecting the market value on the grant date. The vesting schedule spans four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on Mr. Sterling's continued employment. These options have a 10-year term.

2Flo Ventures announces the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. She has nearly two decades of experience in the biopharmaceutical industry, including roles at Chinook Therapeutics and Otsuka Pharmaceuticals. Dr. Jones-Burton's achievements include a $3.2 billion acquisition by Novartis and multiple industry awards. Her appointment aims to enhance 2Flo's portfolio, which includes companies like Cancer IQ and Vivacelle Bio. Dr. Jones-Burton's expertise aligns with 2Flo's mission of advancing health equity and supporting innovative healthcare solutions.

bluebird bio has appointed O. James Sterling as its new Chief Financial Officer (CFO), effective June 10, 2024. Sterling, who previously served as CFO at Renalytix plc, brings extensive experience in healthcare and capital markets. He succeeds Chris Krawtschuk, who played a pivotal role in improving the company's cash flow and financial stability. Sterling's appointment comes as bluebird bio faces the task of restating its financial statements for 2022 and 2023, which will delay its 2023 Annual Report and Q1 2024 Form 10-Q filings. This restatement is not expected to affect the company’s cash or revenue.

bluebird bio, Inc. (NASDAQ: BLUE) reported strong first quarter 2024 results with a net revenue of $18.6 million. The company anticipates a total of 85 to 105 patient starts for its FDA approved therapies in 2024. Despite a delay in filing financial statements due to a restatement, bluebird bio remains confident in its financial position.

bluebird bio, Inc. (Nasdaq: BLUE) will discuss its first quarter 2024 results and business updates on May 9 at 8:00 a.m. ET. The company will also participate in investor conferences on May 16 and June 12. Investors can access the live webcasts on bluebird bio's website.

bluebird bio, Inc. announced the completion of the first commercial cell collection for LYFGENIA gene therapy, a one-time treatment for sickle cell disease. LYFGENIA was FDA-approved in December 2023 and is the most extensively studied gene therapy for the disease. The cells were collected at Children’s National Hospital in Washington, DC, marking a significant milestone in the treatment of sickle cell disease.

bluebird bio, Inc. (Nasdaq: BLUE) received a notice from Nasdaq due to the delayed filing of its Annual Report on Form 10-K for 2023. The company has until June 24, 2024, to submit a compliance plan. This delay is caused by the need to restate financial statements but is not expected to impact cash position or revenue.